237 related articles for article (PubMed ID: 36096343)
1. Development of selective FGFR1 degraders using a Rapid synthesis of proteolysis targeting Chimera (Rapid-TAC) platform.
Guo L; Liu J; Nie X; Wang T; Ma ZX; Yin D; Tang W
Bioorg Med Chem Lett; 2022 Nov; 75():128982. PubMed ID: 36096343
[TBL] [Abstract][Full Text] [Related]
2. A platform for the rapid synthesis of proteolysis targeting chimeras (Rapid-TAC) under miniaturized conditions.
Guo L; Zhou Y; Nie X; Zhang Z; Zhang Z; Li C; Wang T; Tang W
Eur J Med Chem; 2022 Jun; 236():114317. PubMed ID: 35397401
[TBL] [Abstract][Full Text] [Related]
3. Two-Stage Strategy for Development of Proteolysis Targeting Chimeras and its Application for Estrogen Receptor Degraders.
Roberts BL; Ma ZX; Gao A; Leisten ED; Yin D; Xu W; Tang W
ACS Chem Biol; 2020 Jun; 15(6):1487-1496. PubMed ID: 32255606
[TBL] [Abstract][Full Text] [Related]
4. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins.
Yokoo H; Tsuji G; Inoue T; Naito M; Demizu Y; Ohoka N
Bioorg Chem; 2024 Apr; 145():107204. PubMed ID: 38377822
[TBL] [Abstract][Full Text] [Related]
5. Discovery of E3 Ligase Ligands for Target Protein Degradation.
Lee J; Lee Y; Jung YM; Park JH; Yoo HS; Park J
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235052
[TBL] [Abstract][Full Text] [Related]
6. One-Pot Synthesis of Cereblon Proteolysis Targeting Chimeras via Photoinduced C(sp
Arndt CM; Bitai J; Brunner J; Opatz T; Martinelli P; Gollner A; Sokol KR; Krumb M
J Med Chem; 2023 Dec; 66(24):16939-16952. PubMed ID: 38096359
[TBL] [Abstract][Full Text] [Related]
7. A platform for the rapid synthesis of molecular glues (Rapid-Glue) under miniaturized conditions for direct biological screening.
Li J; Li C; Zhang Z; Zhang Z; Wu Z; Liao J; Wang Z; McReynolds M; Xie H; Guo L; Fan Q; Peng J; Tang W
Eur J Med Chem; 2023 Oct; 258():115567. PubMed ID: 37390512
[TBL] [Abstract][Full Text] [Related]
8. Development of versatile solid-phase methods for syntheses of PROTACs with diverse E3 ligands.
Xu H; Kurohara T; Ohoka N; Tsuji G; Inoue T; Naito M; Demizu Y
Bioorg Med Chem; 2023 May; 86():117293. PubMed ID: 37126968
[TBL] [Abstract][Full Text] [Related]
9. Use of ionic liquids in amidation reactions for proteolysis targeting chimera synthesis.
Eleuteri M; Desantis J; Cruciani G; Germani R; Goracci L
Org Biomol Chem; 2024 May; 22(17):3477-3489. PubMed ID: 38602033
[TBL] [Abstract][Full Text] [Related]
10. Selective Wee1 degradation by PROTAC degraders recruiting VHL and CRBN E3 ubiquitin ligases.
Aublette MC; Harrison TA; Thorpe EJ; Gadd MS
Bioorg Med Chem Lett; 2022 May; 64():128636. PubMed ID: 35231578
[TBL] [Abstract][Full Text] [Related]
11. Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach.
Chen Q; Liu C; Wang W; Meng X; Cheng X; Li X; Cai L; Luo L; He X; Qu H; Luo J; Wei H; Gao S; Liu G; Wan J; Israel DI; Li J; Dou D
ACS Chem Biol; 2023 Jan; 18(1):25-33. PubMed ID: 36606710
[TBL] [Abstract][Full Text] [Related]
12. Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity.
Sinatra L; Yang J; Schliehe-Diecks J; Dienstbier N; Vogt M; Gebing P; Bachmann LM; Sönnichsen M; Lenz T; Stühler K; Schöler A; Borkhardt A; Bhatia S; Hansen FK
J Med Chem; 2022 Dec; 65(24):16860-16878. PubMed ID: 36473103
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of proteolysis-targeting chimeras (PROTACs) as degraders of glutathione peroxidase 4.
Cai M; Ma F; Hu C; Li H; Cao F; Li Y; Dong J; Qin JJ
Bioorg Med Chem; 2023 Jul; 90():117352. PubMed ID: 37257255
[TBL] [Abstract][Full Text] [Related]
14. CRBN ligand expansion for hematopoietic prostaglandin D
Osawa H; Kurohara T; Ito T; Shibata N; Demizu Y
Bioorg Med Chem; 2023 Apr; 84():117259. PubMed ID: 37018877
[TBL] [Abstract][Full Text] [Related]
15. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
[TBL] [Abstract][Full Text] [Related]
16. Target protein localization and its impact on PROTAC-mediated degradation.
Simpson LM; Glennie L; Brewer A; Zhao JF; Crooks J; Shpiro N; Sapkota GP
Cell Chem Biol; 2022 Oct; 29(10):1482-1504.e7. PubMed ID: 36075213
[TBL] [Abstract][Full Text] [Related]
17. Evaluating Ligands for Ubiquitin Ligases Using Affinity Beads.
Dobrodziej J; Dong H; Zimmermann K; Hickey CM
Methods Mol Biol; 2021; 2365():59-75. PubMed ID: 34432239
[TBL] [Abstract][Full Text] [Related]
18. Discovery of IAP-recruiting BCL-X
Zhang X; He Y; Zhang P; Budamagunta V; Lv D; Thummuri D; Yang Y; Pei J; Yuan Y; Zhou D; Zheng G
Eur J Med Chem; 2020 Aug; 199():112397. PubMed ID: 32388279
[TBL] [Abstract][Full Text] [Related]
19. Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression.
Wang K; Dai X; Yu A; Feng C; Liu K; Huang L
J Exp Clin Cancer Res; 2022 Sep; 41(1):289. PubMed ID: 36171633
[TBL] [Abstract][Full Text] [Related]
20. Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood-Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2.
Liu X; Kalogeropulou AF; Domingos S; Makukhin N; Nirujogi RS; Singh F; Shpiro N; Saalfrank A; Sammler E; Ganley IG; Moreira R; Alessi DR; Ciulli A
J Am Chem Soc; 2022 Sep; 144(37):16930-16952. PubMed ID: 36007011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
